Keywords
Benign hyperplasia
prostate
Niger
How to Cite
Abstract
Introduction :
Surgical treatment of benign prostatic hyperplasia (BPH) is a common procedure in adult surgery. The aim of this study was to describe the epidemiological, diagnostic, and therapeutic aspects of benign prostatic hyperplasia in the Tillabéry region.
Methodology :
This was a retrospective study covering the period from January 1, 2019, to December 31, 2022 (4 years) involving patients who underwent surgery for BPH at the Tillabéry Regional Hospital Center.
Results :
The frequency of BPH was 9.23% of all abdominal surgery. The average age of patients was 69.90% (range: 50 to 90 years). The most affected age group was between 61 and 70 years, accounting for 43.4%. Patients from rural areas accounted for 76.6%. Urinary retention was the reason for consultation in 92% of cases. The prostate appeared benign on TR in 92% of cases. PSA was normal in 22.3% of cases. The average prostate volume on ultrasound was 95.58 cc. Isolated BPH accounted for 85% of cases. Inguinal hernia repair was the most common surgical procedure, accounting for 5.14%. The average length of postoperative hospitalization was 6.20 days (range : 1 to 14 days). Suppuration of the surgical wound was observed in 4%. Five deaths were recorded, representing 2.90%.
Conclusion :
BPH surgery is a common procedure at the Tillabéry Regional Hospital. It primarily affects elderly patients. Raising awareness about early diagnosis and treatment can reduce morbidity and mortality.
References
1. Madersbacher S, Sampson N, Culig Z. Pathophysiology of benign prostatic hyperplasia and benign prostatic enlargement: a mini-review. Gerontology. 2019;65(5):458-64.
2. Halidou M, Adamou H, Diongolé H, Amadou MMI, Adamou M. Prise en charge chirurgicale de l’hypertrophie bénigne de la prostate (HBP) : à propos de 123 patients colligés à l’Hôpital National de Zinder (HNZ). Ann Univ Abdou Moumouni Niamey. 2015;2:149-56.
3. Diakité ML, Sissoko I, Berthé HJG, Kanté M, Coulibaly MT, Traoré B, et al. Panorama des tumeurs prostatiques dans le service d’urologie du CHU Point G. Health Sci Dis. 2019;20(3):26-31.
4. Das K, Buchholz N. Benign prostate hyperplasia and nutrition. Clin Nutr ESPEN. 2019;33:5-11.
5. Descazeaud A, Robert G, Delongchamps NB, Cornu JN, Saussine C, Haillot O, et al. Bilan initial, suivi et traitement des troubles mictionnels en rapport avec l'hyperplasie bénigne de prostate : recommandations du CTMH de l’AFU. Prog Urol. 2012;22(16):977-88.
6. Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2013;64(1):118-40.
7. Sarma AV, Wei JT. Clinical practice. Benign prostatic hyperplasia and lower urinary tract symptoms. N Engl J Med. 2012;367(3):248-57.
8. Kim EH, Larson JA, Andriole GL. Management of benign prostatic hyperplasia. Annu Rev Med. 2016;67:137-51.
9. Dornbier R, Pahouja G, Branch J, McVary KT. The new American Urological Association benign prostatic hyperplasia clinical guidelines: 2019 update. Curr Urol Rep. 2020;21(9):32.
10. Dahm P, Brasure M, MacDonald R, Olson CM, Nelson VA, Fink HA, et al. Comparative effectiveness of newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia: a systematic review and metaanalysis. Eur Urol. 2017;71(4):570-81.
11. Zhong J, Feng Z, Peng Y, Liang H. A systematic review and meta-analysis of efficacy and safety following holmium laser enucleation of prostate and transurethral resection of prostate for benign prostatic hyperplasia. Urology. 2019;131:14-20.
12. Alexander CE, Scullion MM, Omar MI, Yuan Y, Mamoulakis C, N’Dow JM, et al. Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction. Cochrane Database Syst Rev. 2019;12(12):CD009629.
13. Pham H, Sharma P. Emerging, newlyapproved treatments for lower urinary tract symptoms secondary to benign prostatic hypertrophy. Can J Urol. 2018;25(2):9231-7.
14. Lezrek M, Ameur A, Jira H, Beddouch A. Hémostase dans l’adénomectomie prostatique transvésicale selon la technique de Denis modifiée : à propos de 20 cas. Ann Urol. 2003;37(3):123-6.
15. Nickel JC, Aaron L, Barkin J, Elterman D, Nachabé M, Zorn KC. Guide de pratique de l’Association des urologues du Canada sur les symptômes du bas appareil urinaire chez l’homme et l’hyperplasie bénigne de la prostate (SBAUH/HBP) : mise à jour de 2018. Can Urol Assoc J. 2018;12(10):303-12.
16. Han M, Partin AW. Retropubic and suprapubic open prostatectomy. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Campbell-Walsh Urology. 9th ed. Philadelphia: Saunders Elsevier; 2007. p. 2695-703.
17. Brookes ST, Donovan JL, Peters TJ, Abrams P, Neal DE. Sexual dysfunction in men after treatment for lower urinary tract symptoms: evidence from randomised controlled trial. BMJ. 2002;324(7345):1059-61.
18. Adakal O, Rouga MM, Abdoulaye MB, Adamou H, Maikassoua M, Mounkeila I, et al. Hypertrophie bénigne de la prostate au Centre Hospitalier Régional de Maradi : aspects cliniques, thérapeutiques et pronostiques. Health Sci Dis. 2021;22(11):93-7.
19. Fall PA, Gueye SM, Ndoye AK, Diao B, Thiam OBK, Abdallahi MOC, et al. Mortalité et morbidité précoces après adénomectomie prostatique par voie transvésicale. Afr J Urol. 2002;8(1):20-3.
Metrics
Downloads
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2026 M Ousmane Manzo, M Halidou, O Karimoune Mossi, A Yacouba Moumouni, Y Bokatounga, H Seydou, M Saadou Ibrahim, M Dambaki, A Soumana